Pages that link to "Q37320354"
Jump to navigation
Jump to search
The following pages link to Targeting DNA methylation (Q37320354):
Displaying 50 items.
- CpG Island Methylation in Colorectal Cancer: Past, Present and Future (Q24597977) (← links)
- Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine (Q24608659) (← links)
- An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes (Q24622700) (← links)
- Epithelial-Mesenchymal Transition and Breast Cancer (Q26773055) (← links)
- Epigenetics advancing personalized nanomedicine in cancer therapy (Q27010637) (← links)
- Epigenetics meets radiation biology as a new approach in cancer treatment (Q27014984) (← links)
- Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response (Q27694612) (← links)
- Epigenetic polypharmacology: from combination therapy to multitargeted drugs (Q28067666) (← links)
- The complexity of the Nrf2 pathway: beyond the antioxidant response (Q28389296) (← links)
- DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis (Q28484901) (← links)
- DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status (Q28544885) (← links)
- Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis (Q28589092) (← links)
- Selective inhibition of tumor oncogenes by disruption of super-enhancers (Q29617301) (← links)
- Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives (Q30570945) (← links)
- Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity (Q31101656) (← links)
- Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. (Q33393266) (← links)
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study (Q33425338) (← links)
- Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells (Q33559964) (← links)
- Tackling the methylome: recent methodological advances in genome-wide methylation profiling (Q33600124) (← links)
- Demethylating Agents in the Treatment of Cancer (Q33678040) (← links)
- Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission (Q33723714) (← links)
- Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies (Q33762936) (← links)
- Epigenetic changes in the myelodysplastic syndrome. (Q33767309) (← links)
- Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human (Q33862548) (← links)
- A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. (Q33918412) (← links)
- Mechanisms of resistance to decitabine in the myelodysplastic syndrome. (Q33999539) (← links)
- Application of epigenome-modifying small molecules in induced pluripotent stem cells (Q34031951) (← links)
- Chromatin proteins and modifications as drug targets (Q34038652) (← links)
- Epigenetics and cancer (Q34085532) (← links)
- Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. (Q34101643) (← links)
- Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition (Q34129835) (← links)
- Current limitations and future opportunities for epigenetic therapies. (Q34195077) (← links)
- Targeting DNA methylation for epigenetic therapy (Q34258037) (← links)
- Leukaemogenesis: more than mutant genes (Q34275371) (← links)
- Cancer chemoprevention by dietary polyphenols: promising role for epigenetics (Q34279875) (← links)
- Aberrant WNT/β-catenin signaling in parathyroid carcinoma (Q34360642) (← links)
- Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics (Q34465331) (← links)
- Different effects of valproic acid on photoreceptor loss in Rd1 and Rd10 retinal degeneration mice (Q34476181) (← links)
- Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2 (Q34496410) (← links)
- Epigenetic changes in Basal Cell Carcinoma affect SHH and WNT signaling components (Q34532204) (← links)
- Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer (Q34621606) (← links)
- CpG methylation recruits sequence specific transcription factors essential for tissue specific gene expression (Q34636402) (← links)
- An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer (Q34802527) (← links)
- S100A4 Expression in Xenograft Tumors of Human Carcinoma Cell Lines Is Induced by the Tumor Microenvironment (Q34839397) (← links)
- Translational application of epigenetic alterations: Ovarian cancer as a model (Q35085782) (← links)
- Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis (Q35147669) (← links)
- Targeting components of epigenome by small molecules (Q35214645) (← links)
- Cancer epigenetics: linking basic biology to clinical medicine. (Q35348043) (← links)
- WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix (Q35479045) (← links)
- DNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology (Q35647894) (← links)